SEC filings and other documents

AI-powered healthcare platform drives pharma engagement and revenue growth.

Directors elected, executive pay and equity plan increase approved, evergreen provision rejected.

AI-powered point-of-care platform drives pharma ROI and growth through EHR integration and DSPs.

Q1 revenue exceeded expectations, but 2026 guidance was lowered amid ongoing client and macro pressures.

Scalable platform drives pharma brand engagement and revenue growth in a large digital market.

Record 2025 growth, higher margins, and strong cash flow set stage for cautious but optimistic 2026.

Strong revenue visibility and margin expansion support optimistic long-term growth outlook.

Q2 revenue up 55% year-over-year, profitability restored, and 2025 guidance raised.

Revenue up 11% in Q1 2025; guidance raised on strong pipeline and subscription growth.

Strong Q4 results, margin gains, and DAAP growth set up a robust outlook for 2025.

Q3 revenue up 30% to $21.3M; 2024 guidance set at $88–$92M with strong HCP and DAP momentum.

36% revenue growth and strong DAAP momentum, with high confidence in full-year targets.